Company Overview
About Kriya Therapeutics
Kriya Therapeutics is a gene therapy company founded in 2019 by Saket Bhargava and Chintan Shah, headquartered in Research Triangle Park, North Carolina. The company is building a platform for adeno-associated virus (AAV) gene therapy specifically targeting chronic metabolic and cardiovascular diseases — conditions where a single gene therapy treatment could potentially replace a lifetime of injectable or oral medications. Kriya's therapeutic thesis is that gene therapy, historically applied to rare genetic diseases, can be extended to larger-prevalence conditions like type 2 diabetes, obesity, and lipid disorders — unlocking much larger commercial markets than orphan drug gene therapy programs.
Business Model & Competitive Advantage
Kriya's core differentiation is its proprietary vector engineering platform, which optimizes AAV capsid design, promoter selection, and payload construct to improve tissue specificity, reduce immunogenicity (the immune system's reaction to the viral vector), and enable redosing — long-standing barriers to broader gene therapy adoption. The platform integrates de novo construct design, targeted sequence modification, and data analysis tools, enabling Kriya to systematically engineer improved vectors rather than relying on naturally occurring AAV serotypes. This computational and synthetic biology capability is the central R&D asset the company is building toward IND-enabling studies and eventual clinical trials.
Competitive Landscape 2025–2026
Kriya Therapeutics raised a $150M Series C in 2022 led by Premji Invest (the family office of Wipro's Azim Premji), with participation from Mubadala Investment Company, Decheng Capital, Foresite Capital, and others — bringing total funding to $270M. The company is building manufacturing capabilities and pursuing multiple pipeline programs. Kriya competes in the gene therapy developer space with BioMarin Pharmaceutical, Spark Therapeutics (Roche), Ultragenyx Pharmaceutical, and a number of well-capitalized private gene therapy startups targeting overlapping disease areas and AAV platform technology.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Kriya Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Kriya Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Kriya Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Kriya Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →